The Oncologic Drugs Advisory Committee (ODAC) voted 6–5 that combining ramucirumab combined with established first-line EGFR-directed therapy had a favorable risk-benefit profile for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC), but committee members debated whether the combination would fill an unmet need for these patients. The committee also expressed concern that the drugs sponsor, Eli Lilly, would market the combination appropriately.

Read more about the committee members voting decisions by clicking here.